Kestra Medical Technologies, Ltd. (KMTS) Stock Price & Analysis
Kestra Medical Technologies, Ltd. (KMTS) rose 0.91% to USD 19.92 as of June 10, 2026 at 04:41 UTC, according to Nexqual real-time market data.
KMTS last closed at USD 19.74; the session ranged USD 19.08–20.6 on volume of 396,886 shares. Market capitalization is $1.16B, with a 52-week range of USD 13.25–30 (NMS). Source: Nexqual, June 10, 2026 at 04:41 UTC.
Key Statistics (as of June 10, 2026 at 04:41 UTC)
| Price | USD 19.92 |
|---|---|
| Change | ▲ 0.91% (up) |
| Previous Close | USD 19.74 |
| Open | USD 19.75 |
| Day Range | USD 19.08 – 20.6 |
| 52-Week Range | USD 13.25 – 30 |
| Volume | 396,886 shares |
| Market Cap | $1.16B |
| Exchange | NMS |
Technical Analysis (KMTS)
Nexqual's technical model rates KMTS "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:41 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.98 (neutral) |
| vs SMA50 | Below (USD 20.67) |
| MACD | -0.38 (negative) |
Analyst Ratings (KMTS)
Wall Street analysts rate KMTS "Strong Buy" based on 7 analysts, with a mean price target of USD 27.71 (range USD 17–30), per Nexqual as of June 10, 2026 at 04:41 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 27.71 |
| High Target | USD 30 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (KMTS)
| Next Earnings Date | 2026-03-17 |
|---|---|
| EPS Estimate | USD -0.58 |
| Revenue Estimate | $26.48M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-01-31 | USD -0.4 vs est -0.6 ▲ beat |
| 2025-10-31 | USD -0.45 vs est -0.56 ▲ beat |
| 2025-07-31 | USD -0.36 vs est -0.78 ▲ beat |
| 2025-04-30 | USD -1.15 vs est -0.53 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:41 UTC.
Financials & Fundamentals (KMTS)
| Total Revenue | $83.72M |
|---|---|
| Revenue Growth (YoY) | +62.70% |
| Gross Margin | +48.75% |
| Operating Margin | -141.60% |
| Profit Margin | -172.99% |
| ROE | -92.65% |
| Debt / Equity | 16.16 |
| Current Ratio | 7.32 |
| Total Cash | $291.32M |
| Total Debt | $46.55M |
| Free Cash Flow | $-74.89M |
Source: Nexqual, June 10, 2026 at 04:41 UTC.
Financial Health Score (KMTS)
Nexqual rates Kestra Medical Technologies, Ltd.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:41 UTC.
| Growth | Strong — Revenue +63% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $291M cash vs $47M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$75M, burning cash |
| Efficiency | Critical — ROE -93%, ROA -36.8% |
Ownership (KMTS)
| Insider Ownership | +5.21% |
|---|---|
| Institutional Ownership | +102.85% |
| Shares Outstanding | 58.37M |
| Float | 32.75M |
| Short % of Float | +9.30% |
Source: Nexqual, June 10, 2026 at 04:41 UTC.
Leadership (KMTS)
Kestra Medical Technologies, Ltd. is led by Brian Webster (age 61), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 04:41 UTC.
| Founder, President, CEO & Director | Brian Webster (age 61) |
|---|---|
| Co-Founder, General Counsel, Chief Administrative Officer, Secretary & Director | Traci S. Umberger (age 62) |
| Chief Financial Officer | Vaseem Mahboob (age 56) |
| Vice President of Investor Relations | Neil Bhalodkar |
| Senior Vice President of Marketing | Debra Schotz (age 55) |
Major Backers & Investors (KMTS)
Notable institutional backers of Kestra Medical Technologies, Ltd. include Bain Capital Investors Llc, Price (T.Rowe) Associates Inc, FMR, LLC, according to Nexqual as of June 10, 2026 at 04:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bain Capital Investors Llc | 43.12% |
| Price (T.Rowe) Associates Inc | 12.36% |
| FMR, LLC | 9.8% |
| T. Rowe Price | 5.72% |
| Andera Partners | 4.62% |
| Fidelity | 4.51% |
| Yu Fan | 3.91% |
| Brown Advisory Inc. | 2.95% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.97% |
Source: Nexqual, June 10, 2026 at 04:41 UTC.
From Kestra Medical Technologies, Ltd.'s Latest SEC 10-K Filing (filed 2025-07-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company.
- It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected.
- The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
- Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBNX | Beta Bionics, Inc. | USD 14.39 | ▲ 3.6% |
| CBLL | CeriBell, Inc. | USD 18.5 | ▲ 1.37% |
| HTFL | Heartflow, Inc. | USD 28.67 | ▲ 2.03% |
| CARL | Carlsmed, Inc. | USD 11.29 | ▲ 1.99% |
| MAZE | Maze Therapeutics, Inc. | USD 23.93 | ▼ 1.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:41 UTC. This page is informational and not investment advice.